Patient Selection for Transcatheter Aortic Valve Replacement  by Mack, Michael J. et al.
Journal of the American College of Cardiology Vol. 62, No. 17, Suppl S, 2013
 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.08.707Patient Selection for
Transcatheter Aortic Valve Replacement
Michael J. Mack, MD, David R. Holmes, MD, John Webb, MD, Alain Cribier, MD,
Susheel K. Kodali, MD, Mathew R. Williams, MD, Martin B. Leon, MDPerspective:
Cautious and Evidence-Based
Michael J. Mack, MD,* David R. Holmes, MDy
Transcatheter aortic valve replacement (TAVR) is trans-
formative technology that offers a new and promising option
for the management of patients with severe aortic stenosis
who are either at high risk for traditional surgical aortic
valve replacement (AVR) or inoperable. A signiﬁcant clinical
experience has been gained in these patients, with an esti-
mated 60,000þ valves having been implanted since the
initial experience was reported in 2002. This extensive
experience is the result of two valves, the Sapien valve
(Edwards Lifesciences, Irvine, California) and the Med-
tronic CoreValve (Medtronic Inc., Minneapolis, Minnesota)
receiving CE Mark regulatory approval in 2007 in Europe
and being available for commercial sale and use since that
time, with an approximately equal proportion of each valve.
Recently, 3 additional valves have received regulatory
approval in Europe, the JenaValve (Jena Valve, Jena,
Germany), Direct Flow (Direct Flow Medical, Inc., Santa
Rosa, California), and the Acurate valve (Symetis, Inc.,
Lausanne, Switzerland). A signiﬁcant amount of val-
uable clinical information regarding the introduction of
transcatheter valves has come from the experience, not only in
Europe, Canada, and Australia, but also from other parts of
the world as well; the Sapien valve has now received regulatory
approval in at least 43 countries worldwide. The lessons
learned in this robust worldwide experience have helped to
facilitate the excellent performance and outcomes of trans-
catheter valve therapy in the U.S. pivotal randomized clinical
trial, the PARTNER (Placement of Aortic Transcatheter
Valves) trial. Indeed, centers outside of the United States have
been generously forthcoming in sharing the full breadth and
depth of their experiences, both positive and negative during
the adoption of this new technology in their countries, and
have signiﬁcantly aided the U.S. experience. Indeed, this
global sharing of information, training, and experience, we
believe, has shortened the learning curve and contributed to
the success of the recent commercial launch of the ﬁrst
approved valve in the United States.Device development and approval processes in the United
States are somewhat different and generally more stringent
than in the rest of the world. A fundamental component of the
U.S. regulatory process is the performance of randomized
clinical trials in addition to registries. The ﬁrst randomized
clinical trial of this technology, the PARTNER trial, has
received great interest and attention, especially given the
meticulous conduct of the trial as well as the results (1–4).
Based upon the results of this single trial, which in actuality is
2 concomitant trials, and the worldwide registry experience,
formal U.S. Food and Drug Administration (FDA) approval
has now occurred (5). After this approval, there were important
considerations relevant to the expansion of this technology
beyond the sites that had participated in the pivotal trial. These
considerations included clear deﬁnitions of proper patient selec-
tion, heart center experience, and operator selection criteria, as
well as procedural performance. At this point, one needs to
consider what lessons can be learned from the PARTNER trial
as well as from the commercial experience outside of the United
States that will help facilitate the safe, effective, and reasonable
implementation of TAVR in this country.
Randomized clinical trials form the highest level of
evidence available for evaluating new therapeutic strategies.
Despite implantation in over 60,000 patients worldwide and
an abundance of single-center and multicenter registry data,
there is only 1 randomized trial, the PARTNER trial,
comparing patients receiving TAVR to the existing stan-
dards of care, medical therapy for inoperable patients, and
surgical AVR for high-risk, operable patients. This trial
enrolled 1,057 patients in 2 arms, 1 of which included
patients with severe, symptomatic aortic stenosis, who either
were deemed inoperable (n = 358) or were judged to be at
high risk for surgical AVR (n = 699). The inoperable arm
(Cohort B) was randomized between transfemoral AVR and
medical therapy, which included balloon aortic valvuloplasty
in the majority of patients. The high-risk arm (Cohort A)
randomized patients between transcatheter AVR (trans-
femoral or transapical approach) and surgical AVR. Both
arms of the trial met the pre-deﬁned primary endpoint. In the
inoperable patients, TAVR was found to be superior
to medical therapy for mortality at 1 year by an absolute
difference of 20%. These results have recently been deter-
mined to be sustained and even more beneﬁcial at 2 years (4).
Table 1
Joint Initiatives of the Professional Societies to
Facilitate the Safe and Effective Introduction of TAVR
Professional society overview of TAVR
Operator and institutional requirements for transcatheter valve repair and
replacement
Expert consensus document on TAVR
National coverage determination request
TVT (Transcatheter Valve Therapy) national registry
TAVR ¼ transcatheter aortic valve replacement.
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S2In the high-risk surgical patients, TAVR also met the
primary endpoint of the trial by being noninferior to surgical
AVR for mortality at 1 year. These results are likewise quite
positive, and regulatory approval for commercial sale of the
Sapien valve for use in inoperable patients was granted in
November 2011. A second FDAExpert Panel recommended
approval of the valve for use in high-risk, operable patients,
and it was approved by the agency in late 2012.
However, the results of any randomized controlled trials
need to be considered in the context in which they were
obtained. Only when the parameters under which the study
was performed are well understood, can the results of this or
any randomized trial be reasonably expected to be “gener-
alizable” when applied in the “real world.” The results of the
PARTNER trial were obtained in 25 centers: 22 in the
United States; 2 in Canada; and 1 in Germany. All centers
had signiﬁcant previous experience in the surgical treatment
of aortic stenosis and in the management of structural heart
disease. The evidence of this expertise is the observed to
expected ratio of 0.68 in the surgical arm of the PARTNER
trial, indicating better than expected surgical results in these
high-risk patients. As a condition of participation in the
trial, all centers had a multidisciplinary heart team in place
managing all aspects of patient care, including patient
evaluation and selection, implantation of the transcatheter
valve, and post-operative care.
The multidisciplinary heart team consists of interventional
and general cardiologists, cardiac surgeons, imaging special-
ists, anesthesiologists, and allied health personnel. In addi-
tion, each patient selected by the multidisciplinary heart team
as candidates for TAVR therapy at the clinical sites were
presented to a national committee that included a minimum
of 2 experienced surgeons and interventional cardiologists
who approved the patient’s candidacy. All trial results were
monitored and adverse events adjudicated by a separate and
independent clinical events committee. The question there-
fore is: Can the results of this trial, which were obtained
in centers of excellence with a signiﬁcant supporting infra-
structure of both personnel and facilities in place, be gen-
eralizable to other populations and other centers after
commercial regulatory approval? If so, can the conditions
present at the trial sites, which in all likelihood contributed
to the excellent results, be replicated in the real world?
The American College of Cardiology (ACC) and the
Society of Thoracic Surgeons (STS) are working together
and with the other professional societies in the ﬁeld to help
promote the “rational dispersion” of this promising new
technology into the United States. The goal of these
initiatives is to help facilitate the replication of the excellent
results of the PARTNER trial as well as those results ob-
tained in clinical registries in Europe in commercial use in
this country. It is hoped that in this way, this trans-
formational technology can fulﬁll its great potential and
positively affect the care of these very high-risk patients.
These initiatives are multifaceted and address all aspects of
clinical introduction (Table 1).Professional society overview of TAVR. Simultaneously,
the ACC and the STS recently published a perspective of the
ﬁeld in their respective society journals (6,7). This overview
provided recommendations for a pathway to optimize the
clinical introduction of this technology. This path includes
performance of the procedures by a multidisciplinary heart
team, in valve centers of excellence, which have suitable
facilities including hybrid operating rooms or modiﬁed
catheterization laboratories with state-of-the-art imaging
capabilities. In addition, centers need to be staffed by sufﬁ-
cient supporting personnel to provide the robust level of care
needed by these frequently ill and debilitated patients. In
this joint document, it is also recommended that centers
should have access to adequate numbers of patients with
valvular heart disease in order to provide sufﬁcient procedural
volume and cadence to maintain proﬁciency. The emphasis in
new centers should be on building programs, similar to
transplant programs, and not just on performing procedures.
Furthermore, the overview recommends mandatory partici-
pation in a newly constructed national transcatheter valve
registry, which will be described in more detail here.
Operator and institutional requirements for transcatheter
valve repair and replacement. This is a 4-society guideline
document led by the Society of Catheterization and
Angiographic Intervention and includes the American
Association for Thoracic Surgery, the ACC, and the STS (8).
This document outlines recommendations for structural
cardiology and valve surgery operator and center requirements
to be able to qualify for access to TAVR technology (Table 2).
The goal of the guidelines is to provide criteria that maximize
the opportunity to provide safe and effective dispersion of
TAVR into new centers, yet not restrict access to care
for patients in need of this therapy. It is estimated that approx-
imately 400 of the 1,150 cardiac centers in the United States
that are currently performing AVR would meet these initial
criteria. To date, an estimated 260 centers are performing
TAVR in the United States.
Expert consensus document on TAVR. The 4 afore-
mentioned societies in collaboration with 8 other societies in
specialty ﬁelds participating in TAVR and related aspects
have written a consensus document assessing all aspects of
TAVR-related patient care (9). This document helps to
deﬁne the current state of TAVR practice and frame the
questions that need to be addressed as more experience is
gained with this procedure.
Table 2
Recommendations for Operator and
Institutional Requirements for TAVR
Intervention
Programd1,000 catheterizations/400 PCI per year
Operatorsd100 structural procedures lifetime or 30 L-sided structural
procedures per year (60% should be BAV)
Surgery
Programd50 total AVR per year, of which at least 10 are high risk
(STS score 6%)
Operatorsd100 AVR career, of which at least 10 are high risk (STS 6%) or
25 AVR per year or 50 AVR in 2 years (at least 20 in the last year before
initiating TAVR)
Outcomes for continued certiﬁcation for both new and existing TAVR programs
applies to “inoperable” (PARTNER Cohort B) TAVR patients
30-day all-cause mortality <15%
30-day all-cause neurological events, including transient ischemic attack,
<15%
Major vascular complication <15%
>90% institutional follow-up
60% 1-year survival rate for nonoperable patients
All cases must be submitted to a single national database
AVR ¼ aortic valve replacement; BAV ¼ bicuspid aortic valve; L-sided ¼ left-sided; PARTNER ¼
Placement of Aortic Transcatheter Valves; PCI ¼ percutaneous coronary intervention; STS ¼ Society
of Thoracic Surgeons; TAVR ¼ transcatheter aortic valve replacement.
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regarding transcatheter valve therapy. ACC and STS
have also joined forces in an initiative to educate cardiolo-
gists, surgeons, and all members of the multidisciplinary
heart team in all aspects of TAVR. The ﬁrst course occurred
in December 2011, and courses continued through April
2013. Although it is the responsibility of device manufac-
turers to effectively train operators in the safe and effective
use of their speciﬁc device, the professional societies will
provide educational opportunities in the broader ﬁeld of
aortic stenosis disease management.
National coverage determination. The ACC and the
STS have worked closely with the Centers for Medicare &
Medicaid Services (CMS) to request national coverage so thatTable 3 Highlights of the NCD for TAVR
TAVR is covered for the treatment of symptomatic aortic valve stenosis when furnished acc
The procedure has received FDA pre-market approval for that system’s FDA-approved
Two cardiac surgeons have evaluated the patient’s suitability for open AVR surgery
The patient is under the care of a heart team: a cohesive, multidisciplinary team of m
TAVR must be furnished in a hospital with the appropriate infrastructure that includes:
On-site heart valve surgery program
Cardiac catheterization lab or hybrid operating room/catheterization lab equipped with
Qualiﬁcations to begin a TAVR program for heart teams without TAVR experience: The he
Intervention
Programd1,000 catheterizations/400 PCI per year
Operatorsd100 structural procedures lifetime or 30 L-sided structural procedures p
Surgery
Programd50 total AVR per year, of which at least 10 are high risk (STS 6%)
Operatorsd100 AVR career, of which at least 10 are high risk (STS 6%) or 25 AV
The heart team’s interventional cardiologist(s) and cardiac surgeon(s) must jointly par
The heart team and hospital are participating in a prospective, national, audited regis
TAVR is covered for uses that are not expressly listed as an FDA-approved indication w
TAVR is not covered for patients in whom existing comorbidities would preclude the e
FDA ¼ U.S. Food and Drug Administration; NCD ¼ national coverage determination; other abbreviationsMedicare beneﬁciaries can undergo TAVR procedures (10).
A uniform national coverage policy ensures that all patients
who meet the criteria as set forth by the FDA label of the
device will have access to appropriate care. It will also allow
for the ability to evaluate TAVR use in “off-label” patients
by a “coverage with evidence development” approach that
will examine outcomes in “orphan” populations. The national
coverage determination document was published in May
2012, and it indicates that CMS will reimburse for FDA-
approved indications. Currently, the FDA-approved indica-
tion is for the treatment of severe, symptomatic aortic stenosis
of the native aortic valve in inoperable patients (Table 3). It is
intended that off-label use will be reimbursed by coverage
with evidence development studies nested within the TVT
(Transcatheter Valve Therapy) registry. The ﬁrst of these
investigational device exemption studies to examine outcomes
in inoperable patients undergoing alternative access other
than transfemoral approach procedures has recently been
submitted by the professional societies and received approval
by the FDA although that has recently been placed on hold by
the societies. Two more investigational device exemption
studies in other alternative access patients and in patients
who have degenerated surgical bioprostheses and need
“valve-in-valve” TAVR are currently in the submission
process.
The TVT national registry. The 2 professional societies
currently maintain robust clinical databases that capture
procedural outcomes in patients undergoing catheter-based
interventions and cardiac surgery. The ACC’s NCDR
(National Cardiovascular Data Registry), which contains
over 7 million patient records, captures and analyzes
outcomes in approximately 80% of the cardiac catheteri-
zation laboratories in the United States. The STS’s Adult
Cardiac Surgery Database, containing over 4 million
patient records, tracks and analyzes outcomes from over
95% of the 1,150 U.S. institutions performing cardiac
surgery. The 2 professional society databases have partneredording to an FDA-approved indication and when all of the following conditions are met:
indication
edical professionals
a ﬁxed radiographic imaging system
art team must include:
er year (60% should be BAV)
R per year or 50 AVR in 2 years (at least 20 in the last year before initiating TAVR)
ticipate in the intraoperative technical aspects of TAVR.
try.
hen performed within a clinical study.
xpected beneﬁt from correction of the aortic stenosis.
as in Table 2.
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the STS/ACC TVT registry, which will capture outcomes
from all TAVR procedures performed in the United States
(11,12). As well as reporting 30-day procedural outcomes,
the new database module will be linked to the CMS
administrative database to track long-term outcomes of
patients undergoing the procedure. Furthermore, by linking
with the existing clinical databases, comparative effective-
ness and cost-effectiveness research will be able to be per-
formed comparing TAVR with both surgical AVR and
medical therapy. The ultimate goal of creating this database
infrastructure is to have a platform for the clinical experi-
ences with new medical devices to be able to be collated
from the initial regulatory trial submission through post-
market surveillance and through the total life cycle of the
device. This would then have the capability of performing
post-market device surveillance of subsequent device itera-
tions as well as other new devices in the same ﬁeld.
Potentially, this model could then serve as the prototype for
the introduction of medical devices into other subspecialties
of medicine. Participation in a national database by centers
performing TAVR is a requisite for Medicare reimburse-
ment. The STS/ACC TVT registry meets the eligibility
criteria for CMS reimbursement. As of August 2013, 245
centers in the Unites States are enrolling patients in the
registry, with over 8,000 patient records captured to date.
Summary
The professional societies working closely together believe
that this collaborative approach will set a new standard for
the safe and rational dispersion of new technology and
harken a new era in the ﬁeld of cardiovascular disease
management. The 2 specialty areas of cardiology and cardiac
surgery have not always seen “eye-to-eye” over the years
regarding issues of patient management. It is hoped that by
expanding the multidisciplinary heart team approach, which
has proven to be so successful in the introduction of TAVR
in clinical trials in the United States and elsewhere in the
world, to a more global approach, better patient-centric care
and optimization of outcomes in an expanding number of
patients will result.
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Perspective:
Real-World Considerations
John Webb, MD,* Alain Cribier, MDy
Which patients should be considered candidates for trans-
catheter aortic valve replacement (AVR)?One possible answer
is those patients for whom transcatheter AVR is better in
terms of duration or quality of life than the alternatives.Duration of Life
Medical management is a poor option for most symptom-
atic patients with severe aortic stenosis; for such patients
who are refused surgery due to comorbidities, mortality may
reach 50% by 1 year (1). In the randomized PARTNER
(Placement of Aortic Transcatheter Heart Valves) Cohort B
trial (Transfemoral TAVR vs. Medical Management) trial,
there was an absolute 20% reduction in mortality at 1 year as
compared with mortality for medical management (1). By
2 years, this survival advantage had increased to 25%.
This represents a proven survival beneﬁt more dramatic
than surgery for left main disease, reperfusion therapy,
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S5implantable deﬁbrillators, or pretty much anything else
cardiac medicine has to offer.
Transcatheter AVR is the only therapy shown in a ran-
domized trial to reduce mortality in any group of patients
with aortic stenosis (Fig. 1) (1,2). What about open heart
surgerydthe gold standard for management of aortic stenosis?
There are no randomized trials comparing surgical AVR to
medical management, although admittedly long experience
provides a solid basis for recommending surgical AVR to
patients with symptomatic aortic stenosis. But realistically,
many patients refuse or are refused as candidates for open
surgery, often for good reason.
What then of an operable patient with comorbidities, but
in whom surgical risk is very high? From the PARTNER
(Placement of Aortic Transcatheter Heart Valves) Cohort A
trial (TAVR vs. Surgical AVR) trial, we now have a direct
comparison of surgery to transcatheter AVR (3). Was this
comparison representative of the best that transcatheter and
surgical AVR can offer? The simple answer is no. Some of
the best surgical programs were compared with transcatheter
programs that were still learning how to perform a complex
and immature transcatheter procedure with ﬁrst-generation
technology. Despite this, transcatheter AVR handily met
the tests for “noninferiority” in terms of mortality (3.4% vs.
6.5% with surgery, p ¼ 0.07), establishing it as a valid alter-
native to surgery in high-risk patients (Fig. 2).
Were the 2 therapies really “equivalent?” Examine the
“as-treated” analysis that compared mortality 30 days after
the procedure (as opposed to after randomization) with
what is now generally agreed to be the preferred, less in-
vasive transcatheter procedure: transarterial access via the
femoral artery. It is hard not to notice that transarterial
AVR mortality was less than one-half that of surgical AVR
(3.7% vs 8.2%, p ¼ 0.046) (1).
Transcatheter mortality and morbidity will likely continue
to fall as the procedure and technology mature. By way of
example, in the initial PARTNER 1B experience, major vas-
cular complicationsda major driver of mortalitydoccurred
in 16.8% of patients. Subsequently in the larger European
SOURCE XT (Sapien XT Aortic Bioprosthesis Multi-
Region Outcome Registry), this rate fell to 6.7% with low-
proﬁle systems, improved screening, and experience. With
even lower-proﬁle valve delivery systems, many experienced
centers are ﬁnding that major vascular complication rates are
falling into the low single digits (4).
Quality of Life
Symptoms, functional status, and health-related quality of
life can be dramatically improved with transcatheter AVR
(1,3). As compared with surgery, a transcatheter procedure
offers earlier functional improvement, less bleeding, less
atrial ﬁbrillation, less renal failure, earlier mobilization,
a shorter intensive care and hospital stay, and reduced
rehospitalization (3,5). For inoperable patients, transcatheter
AVR has an incremental cost-effectiveness ratio comparableto other therapies generally considered acceptable econom-
ically. In high-risk operable patients, costs are comparable to
surgery, although in intermediate- and low-risk operable
patients, transcatheter AVR may be too costly (6–8).
However, it is reasonable to expect that the costs of trans-
catheter AVR may parallel the ongoing procedural
improvements, reductions in complications, hospital stay,
and increased market competition.
The systolic performance of current transcatheter valves
is comparable or superior to that of surgical valves (4). Para-
valvular leaks are common, although most are mild and well
tolerated. Admittedly, even milder leaks are associated with
poorer late survival, although a cause and effect relationship
is speculative (9). For the most part, post-procedural paravalv-
ular regurgitation is less than pre-procedural valvular regurgi-
tation (10). Ongoing improvements in prosthesis sizing,
positioning, and design are likely to mitigate this concern (11).
Admittedly, long-term durability remains unproven.
However, with a decade of clinical experience we can be
conﬁdent that durability is adequate for the high-risk pop-
ulation currently being treated (12). Although we cannot yet
know whether durability will match that of the best surgical
valves, it is likely to be comparable to that of many widely
used surgical valves. Importantly, favorable experience with
valve-in-valve implants suggests that the procedure might
be more easily repeated than surgery would be (13).
But what about stroke? Embolic stroke may occur with
both transcatheter and surgical AVR. However, for inop-
erable patients, as in the PARTNER Cohort A trial, stroke
risk was overwhelmed by survival beneﬁt. The combined risk
of death or persistent disability due to stroke was dramati-
cally lower with transarterial AVR than with medical therapy
(1). True, for operable patients, as in the PARTNER 1A
trial, early strokes were more frequent after transcatheter as
opposed to surgical AVR (14). However, over 1, 2, and 3
years, the combined risk of death and/or persistent neuro-
logical disability was actually lower with transarterial than
with surgical AVR (1,3), and by 3 years, there were actually
fewer strokes in the transcatheter AVR group (9). Subse-
quent experience in multiple registries suggest that stroke
risk is falling with the development of improvements in
patient selection and technique (5).
Adoption
Industry estimates indicate that adoption of transcatheter
AVR has been rapid in Europe since it was ﬁrst approved in
2007; implants increased 25% in 2011 alone. Germany,
Austria, and Switzerland led with rates of 76 to 96 per million
inhabitants followed by France, Italy, and the United
Kingdom. Even so, a low penetration rate of 17.9% suggests
that the procedure remains underutilized in high-risk surgical
patients (15). Variable rates appeared to bear a relationship to
healthcare spending per capita, transcatheter AVR–speciﬁc
reimbursement systems, and national restrictions on the
number of implanting centers (15).
Figure 1 Event Rates for Death or Stroke with Disability in PARTNER Cohort B
The PARTNER Cohort B study compared transcatheter aortic valve replacement with conventional medical management in “inoperable” patients. Such a severely ill patient might
reasonably ask: What were the chances of being alive in a year without any disability due to stroke in this very early experience? The answer was: about 49% with medical
management, but about 67% with the transcatheter procedure (1). NNT ¼ number needed to treat; Rx ¼ treatment.
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S6Adoption rates in the United States, after becoming the
43rd country to approve transcatheter AVR, have trailed
Europe. This has largely been due to ongoing regulatory
and, more recently, reimbursement concerns. According to
industry estimates, approximately 60,000 patients undergo
aortic valve surgery each year, andmanymore are not referred,
not accepted, or decline surgery (16). These patients, along
with the approximately 10% of surgical candidates that can
be considered “very high-risk,” represent a very large number
of individuals for whom a potential for beneﬁt is clear. The
ongoing PARTNER II (Placement of Aortic Transcatheter
Valves II) and SURTAVI (Safety and Efﬁcacy Study of the
Medtronic CoreValve System in the Treatment of Severe,Figure 2 Event Rates for Death in the PARTNER 1A Trial
The PARTNER 1A trial compared transarterial transcatheter aortic valve replace-
ment (TAVR) and surgical aortic valve replacement (AVR) in high-risk operable
patients (3). A patient might reasonably ask: “What were chances of being alive in
a year?” The answer was: 73.6% with surgery and 77.8% with the transarterial
procedure, but with less morbidity and an additional risk of about 1% of being left
with disability due to stroke. It seems likely that a patient with fewer comorbidities
and with access to newer TAVR devices and a more mature procedure might fare
much better.Symptomatic Aortic Stenosis in Intermediate Risk Subjects
Who Need Aortic Valve Replacement) trials may extend
this level of evidence to an additional 20% of patients at inter-
mediate surgical risk. It is difﬁcult to know when, if ever, we
will see randomized evaluations in the great bulk (w75%) of
patients who are at “low surgical risk.”Nevertheless, a deﬁnite
shift in practice is already evident as the focus shifts from
mortality differences to what many physicians and patients
believe is a clear potential to reduce morbidity with a less inva-
sive procedure.Figure 3
Which Patients With Severe Symptomatic
Aortic Stenosis Should Consider TAVR?
Currently, patients at low surgical risk should undergo surgery. Intermediate-risk
patients should also be offered surgery, although transcatheter aortic valve
replacement (TAVR) can, in selected patients, be a reasonable alternative in
centers with good outcomes. High-risk surgical patients should be evaluated case
by case; many will do better with TAVR. Patients declined surgery should be offered
TAVR unless excess comorbidities make beneﬁt unlikely.
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who might beneﬁt from transcatheter AVR is deciding who
will not. It is increasingly apparent that costly and invasive
therapies in patients with very severe comorbidities or
extreme age sometimes offer little real chance of beneﬁt. It
appears that multidisciplinary oversight will be needed to
ensure that poorly-selected patients with little chance of
beneﬁt are not exposed to futile interventions (Fig. 3).
So, how should transcatheter AVR be disseminated? In the
United States, there are over 1,000 cardiac surgical centers,
with an annual average of only 60 AVR per center and
a concerning average of only 8 per surgeon (16). Neither
transcatheter nor surgical AVR is ever truly a “low-risk”
procedure. Regional centers with a high volume of cases and-
multidisciplinary teams are more likely to achieve optimal
outcomes (16). The implication is that there should be fewer
full service cardiac programs, offering both surgical and trans-
catheter AVR in a more efﬁcient and responsible manner.Summary
The issues are complex, and the risks associated with
transcatheter AVR are signiﬁcant. Nevertheless, the
evidence is mounting that transcatheter AVR will assume
a mainstream, and possibly a dominant, role in the man-
agement of aortic stenosis.Reprint requests and correspondence: Dr. John Webb, St. Paul’s
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An Evolutionary Decade
Susheel K. Kodali, MD,*y Mathew R. Williams, MD,*y
Martin B. Leon, MD*yOver 60,000 transcatheter aortic valve replacement (TAVR)
procedures have been performed worldwide using either the
balloon-expandable Edwards Sapien (Edwards Lifesciences,
Irvine, California) or the self-expanding Medtronic Cor-
eValve (Medtronic Corporation, Minneapolis, Minnesota)
transcatheter heart valve systems. Most of the clinical data are
in the form of prospective or retrospective case registries,
which have been useful in providing “real-world” clinical
outcome experiences, but they lack scientiﬁc rigor. Recent
efforts by the Valve Academic Research Consortium have
helped to standardize endpoint deﬁnitions that will facilitate
ongoing efforts to accurately report and compare study
ﬁndings (1,2).
The most robust evidence-based medicine TAVR
data comes from the randomized PARTNER (Placement
of Aortic Transcatheter Valves) trial, which compared
standard-of-care therapies to TAVR using the Edwards
Sapien valve in high-risk or inoperable patients with severe
symptomatic aortic stenosis (AS) (3,4). The data clearly
demonstrates improved survival with TAVR versus standard
therapy for inoperable patients and equivalent survival
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Important concerns regarding periprocedural TAVR
complications, including vascular and neurological events,
were also raised in the PARTNER trial. After TAVR,
compared with surgery, patients recovered more quickly
with earlier improvement in symptoms and quality-of-life
measures as well as reduced in-hospital length-of-stay
and resource consumption (5,6). A PARTNER trial cost-
effectiveness substudy demonstrated a cost of $50,000 per-
life-year gained with TAVR, which is similar to many
approvedmedical therapies (7) and was comparable to surgery.
The 2-year follow-up results were published last year for
both arms of the PARTNER trial (8,9). In the inoperable
patients, TAVR showed impressive incremental survival
beneﬁt between the ﬁrst and second year after the index
procedure. However, in patients with extreme comorbidities
(Society of Thoracic Surgeons scores >15%), the mortality
beneﬁt of TAVR versus standard therapy was diminished,
suggesting questionable value of performing TAVR in such
patients. Compared with surgery in high-risk patients,
TAVR had similar mortality at 2 years and similar prosthetic
valve function without evidence of structural valve deteriora-
tion. There was no late hazard for increased neurological
events with TAVR versus surgery after the initial periproce-
dural period. Importantly, echocardiography analyses revealed
that even mild paravalvular aortic regurgitation following
TAVR was associated with signiﬁcantly higher 2-year
mortality. This ﬁnding will require further analysis, but
undoubtedly, efforts must be directed to reduce paravalvular
aortic regurgitation after TAVR in the future.
There are several limitations of the PARTNER trial
that should be acknowledged. First, PARTNER represented
the initial experience with TAVR for the majority of inves-
tigator sites, using an early version of the device. Some of the
outcomes may have been negatively affected by operator
inexperience and/or suboptimal device performance. For in-
stance, there were 30% higher vascular complications in
transfemoral TAVR patients comparing the earlier inoperable
cohort versus the later high-risk cohort. Second, the trans-
apical TAVR arm was underpowered and could not be
directly compared with surgery. Finally, valve durability
assessments of this new transcatheter bioprosthesis will
require extended follow-up beyond 2 years.
As operator experience increases and next-generation
devices become available, outcomes following TAVR will
continue to improve. Recently, data were presented from the
PARTNER 2 trial comparing the Sapien XT to the Sapien
transcatheter heart valve for inoperable patients (10).
Mortalities were equivalent with the 2 devices, but vascular
complications were signiﬁcantly less with the Sapien XT
device, which uses a smaller introducer sheath. Data from
these and other randomized trials such as the recently
completed CoreValve U.S. Pivotal Trial will add to the
body of knowledge regarding outcomes after TAVR and
help deﬁne the patient population that may beneﬁt from
this “transformative” therapy.Patient Selection
Around the world, TAVR has been available for clinical
use in severe AS patients who are either inoperable or at high
risk for surgery. Clearly, operative risk assignment is
a continuum, and discrete categories of risk severity are
somewhat subjective. For instance, the so-called inoperable
patient category in PARTNER was based upon a newly
constructed deﬁnition representing the consensus of execu-
tive committee physicians: a >50% chance of death or irre-
versible morbidity after surgery. Our surgical colleagues were
charged with the responsibility to declare that without the
availability of TAVR, a given patient would not be a suitable
candidate for surgery. Clearly, determination of risk is
challenging and requires a multidisciplinary heart team,
including clinical cardiologists, cardiac surgeons, imaging
specialists, and interventional cardiologists. In particular,
surgical input is critical to deﬁne operative risk categories.
In the carefully regulated environment of the PARTNER
trial, all patients were seen by 2 surgeons and then presented
on a national web-based conference call with other surgeons
and interventional cardiologists to adjudicate the risk
assessment. Rigorous oversight is not feasible outside of
a clinical trial environment. Although risk scores provide
useful guidelines (e.g., Society of Thoracic Surgeons score),
they do not capture many of the important variables af-
fecting operative risk, including clinical conditions (e.g.,
frailty, severe chronic obstructive pulmonary disease,
dementia, and hepatic disease) and anatomic factors (e.g.,
porcelain aorta, “hostile” chest, and vulnerable internal
mammary implants). Therefore, risk categories ultimately
must be assigned by an experienced multidisciplinary team
familiar with the subtleties of patient screening. The devel-
opment of a coordinated risk screening process is crucial in
TAVR patient selection. Moreover, risk assessment cannot
be standardized and will vary based upon the previous
experiences and biases of a speciﬁc physician team at
a particular clinical site.
Presently, TAVR should be considered the procedure of
choice for high-risk patients with symptomatic AS who are
not suitable candidates for surgery, have an expected survival
of at least 1 year, and fulﬁll anatomic criteria for the available
devices. In the high-risk operable category, TAVR is
“noninferior” to surgery and should be considered an alter-
native to AVR in carefully selected patients. It is important
to recognize that most of these high-risk patients are elderly
(>80 years of age), and the beneﬁts of TAVR must be
viewed beyond crude mortality metrics and should extend to
the value of earlier recovery and quality-of-life measures. In
PARTNER, shortened intensive care unit and hospital stays
and earlier recovery with reduced symptoms compared with
those of conventional surgery were meaningful beneﬁts,
especially in elderly patients. In addition, concerns of long-
term valve durability are less signiﬁcant in elderly patients
with more limited life expectancies. Discipline in the patient
selection process also requires identifying the category of
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dure, patients experience little improvement in symptoms or
survival. Severe frailty, moderate or severe dementia, severe
chronic obstructive pulmonary disease, and severe congestive
heart failure unrelated to concomitant AS are examples of
conditions that may shift patients from the inoperable to the
futile categories. Such patients may be palliated with balloon
aortic valvuloplasty to diminish symptoms, but deﬁnitive
treatment with TAVR should be judiciously withheld.
Several caveats must be considered in this challenging
patient selection process. Patient choice and referring
physician preferences must be respected but discounted in
importance during patient screening for TAVR. Signiﬁcant
downward “risk drift” should be actively discouraged, espe-
cially in the subgroup of AS patients who are at low or
intermediate risk for surgery. Ongoing randomized clinical
trials in intermediate-risk patients (PARTNER 2 and
SURTAVI [Safety and Efﬁcacy Study of the Medtronic
CoreValve System in the Treatment of Severe, Symptomatic
Aortic Stenosis in Intermediate Risk Subjects Who Need
Aortic Valve Replacement]) should provide evidence-based
clariﬁcation for TAVR treatment possibilities in these
patient subgroups. Some degree of “risk shift” over time is
understandable and appropriate in high-risk patients, as we
have gained worthwhile clinical judgment based upon earlier
TAVR clinical research. For instance, the previous rigorous
criteria for inoperable patients have been softened some-
what, considering the group knowledge acquired over the
past 5 years. In clinical practice, many high-risk patients fall
outside the parameters of a carefully regulated clinical trial.
There are patient groups that would potentially beneﬁt from
TAVR, but are unlikely to be studied in a randomized trial,
including the following: 1) patients with chronic kidney
disease; 2) patients with a degenerated surgical bioprosthesis
(so-called valve-in-valve TAVR); 3) patients with low-ﬂow,
low-gradient AS; and 4) patients with treatable malignancies
or hepatic failure who require deﬁnitive AS therapy before
concomitant conditions can be managed. TAVR should not
be withheld in such patients, but the data should be captured
in a universal TAVR treatment database.
Technology Dispersion
Perhaps an even greater challenge is how to incorporate
this transformative technology into widespread clinical
practice and maintain the excellent results seen to date.
Clearly, TAVR requires a different advanced skill set that
may not be possessed by many surgeons or interventional
cardiologists. Current trainees may have had the opportunity
to gain experience with TAVR in selected clinical trial
centers, and there is an emergence of dedicated fellowships
in structural heart disease. However, this is a nascent
training process and such fellowships or tutorials are limited
in number and lack uniformity. Moreover, busy clinical
practitioners (surgeons and interventionalists) usually are
without sufﬁcient time and ready availability for an extendedtraining experience. As such, intensive short-term training
courses have been devised that incorporate the following
components: 1) guidance in forming a heart valve team;
2) didactic lectures on technical, clinical, and procedural
considerations; 3) simulation models with hands-on access
to treatment devices; 4) imaging workshops including
echocardiography and multislice computed tomography;
5) case presentations with direct feedback to reﬁne the
patient selection processes; 6) case proctoring by experienced
operators for as long as is necessary before certifying a site as
independent to perform TAVR procedures.
Considering the complexity of this training process, the
inherent challenges of forming a cohesive heart valve team
at each institution, and the case volume requirements to
establish and maintain optimal proﬁciency with TAVR, it
would be unacceptable to allow widespread dissemination
of this technology to themajority of surgical and interventional
programs in the United States. Last year, the Society for
Cardiovascular Angiography and Interventions/American
Association for Thoracic Surgery/American College of
Cardiology Foundation/Society of Thoracic Surgeons pub-
lished a consensus document listing guidelines for both
physicians and facilities who desire to participate as TAVR
centers (11). These guidelines are analogous to a credentialing
process for operating physicians as well as institutions on a
national scale, not dissimilar to certiﬁcation of heart transplant
or left ventricular assist device programs. This society-driven
operator and site certiﬁcation concept has advantages and
disadvantages. From a positive standpoint, developing
minimal performance criteria and uniform standards to help
ensure patient safety and optimal TAVR efﬁcacy is laudable
and should be commended. Importantly, consensus criteria
will help to impart a sense of “fairness” in the site selection
process and will defuse potential biases associated with
a sole sponsor-driven process. However, there are numerous
unforeseen political and logistic ramiﬁcations of an overly
rigid and/or conveniently simplistic schema developed by
either societies or the Centers for Medicare and Medicaid
Services. For instance, regional geographic availability to
TAVR centers for patients must be a consideration that over-
rides to some degree absolute case volume requirements.
Competition among centers in urban areas may be problem-
atic, wherein a binary decision to allow or prohibit TAVR
therapy at selected sites will undoubtedly disadvantage the
future viability of many well-respected surgical or interven-
tional programs. Case volumemetrics may be a crude measure
of quality and team skills, because we have observed that many
high-volume centers lack the coordination and resolve to
function as a cohesive heart valve team. Furthermore, younger
physician operators (both interventionalists and surgeons)
may be deﬁcient in overall case volumes but are ideally suited
to help lead a TAVR team based upon advanced imaging
capabilities, recent TAVR training experiences, and a dedica-
tion to the heart team culture. Thus, a more ﬂexible in-depth
approach to operator and site selection is preferred, taking
into account some of the aforementioned subtleties, such
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summarily excluded.
From our vantage point, having been involved in clinical
TAVR procedures for almost 7 years, having performed over
800 TAVR implants, and having trained a signiﬁcant
number of the PARTNER and early commercial U.S.
TAVR sites, we believe that 5 requirements are essential
for TAVR site selection and successful activation. First
and foremost, a multidisciplinary heart valve team must
be established and functional before beginning TAVR
procedures. The team members (including physician and
nonphysician healthcare professionals) are charged with
developing a treatment care strategy for each patient, which
spans the range from case screening, decisions on the
optimal treatment, procedural details, and to post-therapy
management, including support services in and out of hos-
pital. The establishment of an integrated heart valve team is
the most difﬁcult step in the TAVR process and a priori is
the most difﬁcult to assess during site evaluations. Second,
a site must have the institutional infrastructure support to
manage a TAVR program. Investment by hospital admin-
istration in the optimal procedure venue (often a hybrid
operating room/catheterization lab in the United States),
ancillary staff (including nurse coordinators), and intensive
care unit facilities are an absolute necessity to manage elderly
comorbid patients with severe AS. Third, the heart valve
team members must have the necessary blend of experience
and facility with novel technologies to manage the vagaries of
learning a complex and changing device platform. This “ne-
cessary blend” incorporates the notion of sufﬁcient case
volume combined with advanced skills in high-risk patients
from the surgical, interventional, and imaging representa-
tives of the team. Fourth, all sites should enthusiastically
embrace clinical data collection and participation in the
national TVT (Transcatheter Valve Therapy) database.
These data will be irreplaceable to benchmark performance
standards, determine adherence to accepted case selection
criteria, monitor and/or discover procedure- and device-
related complications, and provide the substrate for reim-
bursement decisions now and in the future. Finally, there is
an “X” factor that distinguishes the best performing TAVR
sites. Optimal TAVR requires a level of individual and
institutional dedication and commitment, unlike most other
surgical or interventional procedures. Thus, a site culture
must rapidly evolve that exudes the intensity and passion of
having access to this new life-saving therapy.
Summary
In the past decade, TAVR has clearly changed the treatment
algorithm for patients with AS. The careful and thoughtful
expansion of TAVR in clinical practice will require
evidence-based medicine validation in the form of clinical
research. Ongoing trials with newer devices and in different
patient populations will better deﬁne the role for TAVR
over the next decade. Regulation of TAVR (use and abuse)on a national scale will affect, not only the role of TAVR,
but also the landscape for surgical programs in the future.Reprint requests and correspondence: Dr. Susheel K. Kodali,
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